BofA analyst Tazeen Ahmad raised the firm’s price target on Ultragenyx to $83 from $73 and keeps a Buy rating on the shares. The firm continues to be encouraged by the performance of the company’s commercial franchise and model FY24 Crysvita sales in line with company guidance, the analyst tells investors. The firm continues to highlight Ultragenyx as one of its top picks of 2025 given its catalyst rich pipeline in high unmet need rare disease indicators.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE:
- Inozyme appoints Erik Harris to board of directors
- Ultragenyx receives Breakthrough Therapy Designation for setrusumab
- Ultragenyx provides update on Cyprus2+ study, to submit protocol amendment
- Closing Bell Movers: Ultragenyx Pharmaceutical slips 2% on study update
- Passage Bio appoints Tom Kassberg to board of directors